

Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor

Information for the public

Published: 1 July 2026

www.nice.org.uk

Pirtobrutinib (Jaypirca) is available on the NHS. It is a possible treatment for relapsed or refractory chronic lymphocytic leukaemia in adults who have had a Bruton's tyrosine kinase (BTK) inhibitor. It is only recommended if retreatment with a specific type of BTK inhibitor (covalent), including fixed-duration regimens, is not clinically appropriate for them.

Relapsed means the leukaemia has come back, and refractory means it has not responded well enough to treatment. A fixed-duration regimen is a course of treatment for a fixed amount of time.

If you are not eligible for pirtobrutinib but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on chronic lymphocytic leukaemia](#) may be a good place to find out more.

These organisations can give you advice and support:

- [CLL Support](#), 0800 977 4396
- [Lymphoma Action](#), 0808 800 5555
- [Leukaemia Care](#), 08088 010 444
- [Leukaemia UK](#), 020 8189 9878
- [Blood Cancer UK](#), 0808 2080 888
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-9580-6